PharmTech Drug Digest 11.20
News|Articles|January 31, 2014

AAIPharma Services, Cambridge Major Laboratories Name Executive VP

Author(s)Melanie Sena

Jeff Yuen had been appointed executive vice-president, global quality for combined companies.

AAIPharma Services, a provider of pharmaceutical analytical testing, product development, and manufacturing services, and Cambridge Major Laboratories, a provider of pharmaceutical API development and manufacturing, have appointed Jeff Yuen as executive vice-president, global quality. Yuen has served as food and drug investigator at the State of California’s, Department of Health Services and was a Commander in the US Public Health Service at FDA. He also was GMP auditor, GMP advisor or FDA advisory committee member at National Nutritional Foods Association, Dietary Supplement, and BIOCOM. After leaving the FDA, he led an independent firm focused on FDA compliance and regulatory consulting for the dietary supplement, pharmaceutical, and biotechnology industries.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.